Brenda Aguilar
Overview
Explore the profile of Brenda Aguilar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1903
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akhavan D, Subham S, Jeppson J, Aguilar B, Wong R, Hibbard J, et al.
Cells
. 2024 Jul;
13(13.
PMID: 38994929
Standard-of-care treatment for Glioblastoma Multiforme (GBM) is comprised of surgery and adjuvant chemoradiation. Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated disease-modifying activity in GBM and holds great promise....
2.
Brown C, Hibbard J, Alizadeh D, Blanchard M, Natri H, Wang D, et al.
Nat Med
. 2024 Mar;
30(5):1501.
PMID: 38514871
No abstract available.
3.
Brown C, Hibbard J, Alizadeh D, Blanchard M, Natri H, Wang D, et al.
Nat Med
. 2024 Mar;
30(4):1001-1012.
PMID: 38454126
Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report...
4.
Gutova M, Hibbard J, Ma E, Natri H, Adhikarla V, Chimge N, et al.
Front Immunol
. 2024 Mar;
15:1342625.
PMID: 38449858
Introduction: Despite aggressive standard-of-care therapy, including surgery, radiation, and chemotherapy, glioblastoma recurrence is almost inevitable and uniformly lethal. Activation of glioma-intrinsic Wnt/β-catenin signaling is associated with a poor prognosis and...
5.
Starr R, Aguilar B, Gumber D, Maker M, Huard S, Wang D, et al.
Cancer Res Commun
. 2023 Mar;
3(1):66-79.
PMID: 36968221
Significance: This study reveals how modulating CAR design outside the antigen targeting domain improves selective tumor recognition. Specifically, this work shows improved specificity, persistence, and efficacy of 4-1BB-based IL13-ligand CARs....
6.
Stern L, Gholamin S, Moraga I, Yang X, Saravanakumar S, Cohen J, et al.
Proc Natl Acad Sci U S A
. 2022 Aug;
119(33):e2112006119.
PMID: 35939683
IL13Rα2 is an attractive target due to its overexpression in a variety of cancers and rare expression in healthy tissue, motivating expansion of interleukin 13 (IL13)-based chimeric antigen receptor (CAR)...
7.
Kuo Y, Kuo C, Jenkins K, Hung A, Chang W, Park M, et al.
J Immunother Cancer
. 2022 Jun;
10(6).
PMID: 35728874
Background: Chimeric antigen receptor (CAR) T cells engineered to recognize and target tumor associated antigens have made a profound impact on the quality of life for many patients with cancer....
8.
Wang Z, McWilliams-Koeppen H, Reza H, Ostberg J, Chen W, Wang X, et al.
Cell Stem Cell
. 2022 Apr;
29(4):651-653.
PMID: 35395190
No abstract available.
9.
Wang Z, McWilliams-Koeppen H, Reza H, Ostberg J, Chen W, Wang X, et al.
Cell Stem Cell
. 2022 Mar;
29(4):515-527.e8.
PMID: 35278370
Unlimited generation of chimeric antigen receptor (CAR) T cells from human-induced pluripotent stem cells (iPSCs) is an attractive approach for "off-the-shelf" CAR T cell immunotherapy. Approaches to efficiently differentiate iPSCs...
10.
Brown C, Rodriguez A, Palmer J, Ostberg J, Naranjo A, Wagner J, et al.
Neuro Oncol
. 2022 Jan;
24(8):1318-1330.
PMID: 35100373
Background: Wide-spread application of chimeric antigen receptor (CAR) T cell therapy for cancer is limited by the current use of autologous CAR T cells necessitating the manufacture of individualized therapeutic...